Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innoviva (INVA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Innoviva (INVA) over the last 16 years, with Q3 2025 value amounting to -$16.5 million.

  • Innoviva's Change in Accured Expenses fell 31488.56% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.5 million, marking a year-over-year decrease of 3785.03%. This contributed to the annual value of $3.0 million for FY2024, which is 30320.43% up from last year.
  • Latest data reveals that Innoviva reported Change in Accured Expenses of -$16.5 million as of Q3 2025, which was down 31488.56% from $6.7 million recorded in Q2 2025.
  • Over the past 5 years, Innoviva's Change in Accured Expenses peaked at $9.7 million during Q2 2022, and registered a low of -$16.5 million during Q3 2025.
  • For the 5-year period, Innoviva's Change in Accured Expenses averaged around -$2.0 million, with its median value being -$2.6 million (2024).
  • Per our database at Business Quant, Innoviva's Change in Accured Expenses skyrocketed by 44614.08% in 2022 and then plummeted by 136353.38% in 2024.
  • Innoviva's Change in Accured Expenses (Quarter) stood at -$2.5 million in 2021, then grew by 22.46% to -$1.9 million in 2022, then tumbled by 83.07% to -$3.5 million in 2023, then fell by 12.79% to -$4.0 million in 2024, then plummeted by 314.89% to -$16.5 million in 2025.
  • Its Change in Accured Expenses was -$16.5 million in Q3 2025, compared to $6.7 million in Q2 2025 and -$4.8 million in Q1 2025.